Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|July 5, 2018
Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer
Treatment Regimen for Patients With ALK+ Non-Small Cell Lung Cancer
Advertisement
CASE:ALK+ NonSmall Cell Lung Cancer
March 2017
- A 69-year-old female never-smoker presented with dyspnea, cough and fatigue
- PMH: hypertension managed on losartan 100 mg
- Chest X-ray showed multiple bilateral lung nodules
- Brain MRI, negative for intracranial metastases
- Bronchoscopy was performed with a fine needle aspirate biopsy
- Pathology revealed adenocarcinoma, consistent with a lung primary tumor
- Molecular testing:
- NGS: positive for ALK gene rearrangement
- NGS: negative forEGFR, ROS1, RET, BRAF, KRAS
- IHC: PD-L1 expression in 0% of cells
- The patient was started on therapy with crizotinib
- Follow-up imaging at 3 and 6 months showed marked regression of the lung mass, nodal spread, and bone lesions
January 2018
- After 10 months on crizotinib, the patient reported worsening fatigue, back pain, and dyspnea
- CT showed increased size of the pulmonary masses and bone lesions
- Brain MRI showed disseminated small lesions
- Crizotinib was discontinued and the patient was started on brigatinib
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5